secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003920
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios outlines 2024 milestones; positive Phase 3 mitapivat data in thalassemia; multiple potential approvals by 2026
--------------------------------------------------------------------------------

- Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia met primary endpoint (data Jan 3, 2024).
- NDA for mitapivat in thalassemia planned by end of 2024; potential FDA approval in 2025.
- Four additional Phase 3 readouts expected by end of 2025: ENERGIZE-T, ACTIVATE kids-T, RISE UP, ACTIVATE kids.
- Potential FDA approvals: thalassemia 2025, sickle cell disease 2026, pediatric PK deficiency 2026.
- Cash position expected to support operations and pipeline expansion at least into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312524003920/0001193125-24-003920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312524003920/d275955d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer